<?xml version="1.0" encoding="UTF-8"?>
<xmi:XMI xmlns:provenance="http:///de/fraunhofer/scai/bio/extraction/types/meta/provenance.ecore" xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:meta2="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/meta.ecore" xmlns:meta="http:///de/fraunhofer/scai/bio/extraction/types/meta.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:container="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/container.ecore" xmlns:text="http:///de/fraunhofer/scai/bio/extraction/types/text.ecore" xmlns:structure="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/structure.ecore" xmlns:image="http:///de/fraunhofer/scai/bio/extraction/types/image.ecore" xmlns:documentelement="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <meta:Person xmi:id="1" surname="uimahpc"/>
    <meta:Person xmi:id="6" surname="uimahpc"/>
    <meta:Person xmi:id="11" surname="msood"/>
    <provenance:AgentProvenance xmi:id="16" user="1"/>
    <provenance:AgentProvenance xmi:id="18" user="6"/>
    <provenance:AgentProvenance xmi:id="20" user="11"/>
    <provenance:ActivityProvenance xmi:id="22" componentId="de.fraunhofer.scai.bio.uima.core.reader.XCasMessageReader" startedAtTime="1545" endedAtTime="1552" version="7.1-SNAPSHOT" parameters="132 136 140 144 148 152 156 1559" wasAssociatedWith="16"/>
    <provenance:ActivityProvenance xmi:id="39" componentId="de.fraunhofer.scai.bio.uima.core.reader.XCasMessageReader" startedAtTime="1563" endedAtTime="1570" version="7.1-SNAPSHOT" parameters="208 248 224 240 256 272 184 176" wasAssociatedWith="18"/>
    <provenance:ActivityProvenance xmi:id="56" componentId="de.fraunhofer.scai.bio.uima.mysqlreader.ctgov.reader.MySQLReader" startedAtTime="1577" endedAtTime="1584" version="7.1-SNAPSHOT" parameters="188 164 252 220 260 168 192 264 268 228 212 1591 1595 196" wasAssociatedWith="20"/>
    <provenance:ActivityProvenance xmi:id="79" componentId="de.fraunhofer.scai.bio.uima.onlp.sentencedetector.annotator.OpenNLP_SentenceDetector" startedAtTime="1599" endedAtTime="1606" version="7.1-SNAPSHOT" parameters="216 244 232 236" wasAssociatedWith="18"/>
    <provenance:ActivityProvenance xmi:id="92" componentId="de.fraunhofer.scai.bio.uima.core.writer.XCasMessageWriter" startedAtTime="1613" endedAtTime="1620" version="7.1-SNAPSHOT" parameters="280 204 200 160 172 180" wasAssociatedWith="18"/>
    <provenance:ActivityProvenance xmi:id="107" componentId="de.fraunhofer.scai.bio.uima.documentdecomposer.annotator.DocumentDecomposerAnnotator" startedAtTime="1627" endedAtTime="1634" version="7.1-SNAPSHOT" parameters="284" wasAssociatedWith="16"/>
    <provenance:ActivityProvenance xmi:id="117" componentId="de.fraunhofer.scai.bio.uima.core.writer.XCasMessageWriter" startedAtTime="1641" endedAtTime="1648" version="7.1-SNAPSHOT" parameters="288 292 296 300 304 308" wasAssociatedWith="16"/>
    <meta:Parameter xmi:id="132" key="jmsBroker" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="136" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="140" key="jmsQueue" value="/queue/DocumentDecomposer.patents" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="144" key="jmsTool" value="DocumentDecomposerDeployer (7.1-SNAPSHOT)" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="148" key="documentCollectionName" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="152" key="license" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="156" key="recipients" value="" wasGeneratedBy="22"/>
    <meta:Parameter xmi:id="160" key="jmsSource" value="/queue/ONLPSentenceDetector.en" wasGeneratedBy="92"/>
    <meta:Parameter xmi:id="164" key="recipient" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="168" key="connection" value="jdbc:mysql://flux:30008/aetionomy" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="172" key="jmsBilling" value="creating XCAS" wasGeneratedBy="92"/>
    <meta:Parameter xmi:id="176" key="event" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="180" key="storeResult" value="" wasGeneratedBy="92"/>
    <meta:Parameter xmi:id="184" key="recipients" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="188" key="condition" value="false" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="192" key="password" value="Espe52" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="196" key="event" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="200" key="jmsTool" value="OpenNLP_SentenceDetectorDeployer (7.1-SNAPSHOT)" wasGeneratedBy="92"/>
    <meta:Parameter xmi:id="204" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="92"/>
    <meta:Parameter xmi:id="208" key="jmsBroker" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="212" key="documentCollectionName" value="da520808-d64a-4336-8261-3e397759a010" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="216" key="language" value="en" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="220" key="QueryFile" value="etc/query" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="224" key="jmsQueue" value="/queue/ONLPSentenceDetector.en" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="228" key="offset" value="0" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="232" key="doAbbrevFilter" value="false" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="236" key="typeFilter" value="" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="240" key="jmsTool" value="OpenNLP_SentenceDetectorDeployer (7.1-SNAPSHOT)" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="244" key="lineSeparation" value="false" wasGeneratedBy="79"/>
    <meta:Parameter xmi:id="248" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="252" key="trackingNr" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="256" key="documentCollectionName" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="260" key="Query" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="264" key="username" value="root" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="268" key="limit" value="1" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="272" key="license" value="" wasGeneratedBy="39"/>
    <meta:Parameter xmi:id="276" key="inputString" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="280" key="jmsBroker" value="" wasGeneratedBy="92"/>
    <meta:Parameter xmi:id="284" key="sectionIniFile" value="/home/uimahpc/microservices/etc/sections-patents.ini" wasGeneratedBy="107"/>
    <meta:Parameter xmi:id="288" key="jmsBroker" value="" wasGeneratedBy="117"/>
    <meta:Parameter xmi:id="292" key="jmsIni" value="/home/uimahpc/microservices/etc/jms.ini" wasGeneratedBy="117"/>
    <meta:Parameter xmi:id="296" key="jmsTool" value="DocumentDecomposerDeployer (7.1-SNAPSHOT)" wasGeneratedBy="117"/>
    <meta:Parameter xmi:id="300" key="jmsSource" value="/queue/DocumentDecomposer.patents" wasGeneratedBy="117"/>
    <meta:Parameter xmi:id="304" key="jmsBilling" value="creating XCAS" wasGeneratedBy="117"/>
    <meta:Parameter xmi:id="308" key="storeResult" value="" wasGeneratedBy="117"/>
    <meta:KeyValue xmi:id="312" key="event" value="ExtractHeader ExtractFrontMatter"/>
    <meta:KeyValue xmi:id="316" key="tracking-nr" value="MZ"/>
    <meta:KeyValue xmi:id="320" key="license" value="MDAzMGxvY2F0aW9uIHd3dy5zY2FpLmZyYXVuaG9mZXIuZGUvbXppbW1lcm1hbm4KMDAxY2lkZW50aWZpZXIgdGVzdCBsaWNlbnNlCjAwMjBjaWQgdGltZSA8IDIwNDItMDEtMDFUMDA6MDAKMDAyZnNpZ25hdHVyZSAJPOFDaQbvzzfyMuZOWHaYgFxTnpiSu3K6JZ1ys7Vp1go"/>
    <meta:KeyValue xmi:id="324" key="unit" value="24 [DocElems],53 [Paragraphs]"/>
    <tcas:DocumentAnnotation xmi:id="328" sofa="1524" begin="0" end="10266" language="x-unspecified"/>
    <meta:Header xmi:id="333" sofa="1524" begin="0" end="0" source="Huntington Medical Research Institutes" title="Minocycline in Patients With Alzheimer's Disease" authors="1655" publicationDate="1660" ISSN="NCT01463384" documentConcept="1664"/>
    <provenance:EntityProvenance xmi:id="349" documentID="af5fd4814a6a9d0bf62e8ef65be39ae67e67dd7350c13ea2c34120cdc6127a66" userSuppliedID="NCT01463384" wasDerivedFrom="http://www.scai.fraunhofer.de" workflowProvenance="56 39 79 92 22 107 117" wasGeneratedBy="56" wasAttributedTo="20" documentCollectionName="da520808-d64a-4336-8261-3e397759a010" documentURI="file:/home/msood/workspace/MySQLCTgov2XMI/NCT01463384"/>
    <tcas:DocumentAnnotation xmi:id="367" sofa="1531" begin="0" end="10266" language="x-unspecified"/>
    <meta2:DocumentTitle xmi:id="372" sofa="1531" begin="89" end="177" wasGeneratedBy="56"/>
    <meta2:Abstract xmi:id="380" sofa="1531" begin="684" end="1262" wasGeneratedBy="56"/>
    <container:Section xmi:id="386" sofa="1531" begin="0" end="669" wasGeneratedBy="56" title="Overview:" rhetorical="Overview:"/>
    <container:Section xmi:id="395" sofa="1531" begin="669" end="1264" wasGeneratedBy="56" title="Brief Summary:" rhetorical="Brief Summary:"/>
    <container:Section xmi:id="404" sofa="1531" begin="1264" end="3263" wasGeneratedBy="56" title="Detailed Description:" rhetorical="Detailed Description:"/>
    <container:Section xmi:id="413" sofa="1531" begin="3263" end="4077" wasGeneratedBy="56" title="Criteria:" rhetorical="Criteria:"/>
    <container:Section xmi:id="422" sofa="1531" begin="4077" end="4378" wasGeneratedBy="56" title="Further Study Details:" rhetorical="Further Study Details:"/>
    <container:Section xmi:id="431" sofa="1531" begin="4381" end="4615" wasGeneratedBy="56" title="Design Information:" rhetorical="Design Information:"/>
    <container:Section xmi:id="440" sofa="1531" begin="4618" end="4759" wasGeneratedBy="56" title="Intervention Information:" rhetorical="Intervention Information:"/>
    <container:Section xmi:id="449" sofa="1531" begin="4762" end="7612" wasGeneratedBy="56" title="Outcome Information:" rhetorical="Outcome Information:"/>
    <container:Section xmi:id="458" sofa="1531" begin="7616" end="7659" wasGeneratedBy="56" title="Outcome Analysis Details:" rhetorical="Outcome Analysis Details:"/>
    <container:Section xmi:id="467" sofa="1531" begin="7663" end="7920" wasGeneratedBy="56" title="Outcome Measure Details:" rhetorical="Outcome Measure Details:"/>
    <container:Section xmi:id="476" sofa="1531" begin="7924" end="8080" wasGeneratedBy="56" title="Outcome Values:" rhetorical="Outcome Values:"/>
    <container:Section xmi:id="485" sofa="1531" begin="8083" end="8605" wasGeneratedBy="56" title="Study Outcome Details:" rhetorical="Study Outcome Details:"/>
    <container:Section xmi:id="494" sofa="1531" begin="8608" end="8788" wasGeneratedBy="56" title="Location Details:" rhetorical="Location Details:"/>
    <container:Section xmi:id="503" sofa="1531" begin="8791" end="9764" wasGeneratedBy="56" title="Arm Group Details:" rhetorical="Arm Group Details:"/>
    <container:Section xmi:id="512" sofa="1531" begin="9767" end="10222" wasGeneratedBy="56" title="Baseline Information:" rhetorical="Baseline Information:"/>
    <container:SubSection xmi:id="521" sofa="1531" begin="1263" end="10266" wasGeneratedBy="107" title="DETAILS"/>
    <container:SubSection xmi:id="530" sofa="1531" begin="3273" end="3474" wasGeneratedBy="56" title="Inclusion Criteria." rhetorical="Inclusion Criteria."/>
    <container:SubSection xmi:id="539" sofa="1531" begin="3474" end="4077" wasGeneratedBy="56" title="Exclusion Criteria." rhetorical="Exclusion Criteria."/>
    <container:SubSection xmi:id="548" sofa="1531" begin="4787" end="7612" wasGeneratedBy="56" title="Outcome Details:" rhetorical="Outcome Details:"/>
    <container:SubSection xmi:id="557" sofa="1531" begin="8630" end="8741" wasGeneratedBy="56" title="Facility Details:" rhetorical="Facility Details:"/>
    <container:SubSection xmi:id="566" sofa="1531" begin="8745" end="8788" wasGeneratedBy="56" title="Facility Contact Details:" rhetorical="Facility Contact Details:"/>
    <container:SubSection xmi:id="575" sofa="1531" begin="9793" end="9812" wasGeneratedBy="56" title="Baseline ID:" rhetorical="Baseline ID:"/>
    <container:SubSection xmi:id="584" sofa="1531" begin="9816" end="9858" wasGeneratedBy="56" title="Baseline Measure Details:" rhetorical="Baseline Measure Details:"/>
    <container:SubSection xmi:id="593" sofa="1531" begin="9862" end="10222" wasGeneratedBy="56" title="Baseline Measure Cateogary Details:" rhetorical="Baseline Measure Cateogary Details:"/>
    <meta2:Reference xmi:id="602" sofa="1531" begin="4314" end="4328" wasGeneratedBy="56"/>
    <text:Sentence xmi:id="613" sofa="1531" begin="0" end="667" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="620" sofa="1531" begin="669" end="996" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="627" sofa="1531" begin="997" end="1150" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="634" sofa="1531" begin="1151" end="1262" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="641" sofa="1531" begin="1264" end="1743" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="648" sofa="1531" begin="1744" end="2066" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="655" sofa="1531" begin="2067" end="2230" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="662" sofa="1531" begin="2231" end="2435" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="669" sofa="1531" begin="2436" end="2550" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="676" sofa="1531" begin="2551" end="2671" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="683" sofa="1531" begin="2672" end="2838" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="690" sofa="1531" begin="2839" end="3012" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="697" sofa="1531" begin="3013" end="3261" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="704" sofa="1531" begin="3263" end="3292" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="711" sofa="1531" begin="3294" end="3473" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="718" sofa="1531" begin="3474" end="3493" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="725" sofa="1531" begin="3495" end="3637" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="732" sofa="1531" begin="3639" end="3777" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="739" sofa="1531" begin="3779" end="4075" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="746" sofa="1531" begin="4077" end="4757" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="753" sofa="1531" begin="4759" end="4827" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="760" sofa="1531" begin="4828" end="4918" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="767" sofa="1531" begin="4919" end="5007" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="774" sofa="1531" begin="5008" end="5181" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="781" sofa="1531" begin="5182" end="5435" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="788" sofa="1531" begin="5436" end="5466" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="795" sofa="1531" begin="5467" end="5914" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="802" sofa="1531" begin="5917" end="5939" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="809" sofa="1531" begin="5940" end="6185" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="816" sofa="1531" begin="6186" end="6302" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="823" sofa="1531" begin="6303" end="6382" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="830" sofa="1531" begin="6383" end="6510" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="837" sofa="1531" begin="6513" end="6535" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="844" sofa="1531" begin="6536" end="6688" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="851" sofa="1531" begin="6689" end="6777" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="858" sofa="1531" begin="6778" end="6968" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="865" sofa="1531" begin="6969" end="7131" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="872" sofa="1531" begin="7132" end="7343" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="879" sofa="1531" begin="7344" end="7432" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="886" sofa="1531" begin="7433" end="7495" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="893" sofa="1531" begin="7496" end="7623" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="900" sofa="1531" begin="7626" end="7672" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="907" sofa="1531" begin="7673" end="7755" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="914" sofa="1531" begin="7756" end="7807" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="921" sofa="1531" begin="7808" end="7871" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="928" sofa="1531" begin="7872" end="7932" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="935" sofa="1531" begin="7934" end="8243" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="942" sofa="1531" begin="8244" end="8432" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="949" sofa="1531" begin="8433" end="8754" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="956" sofa="1531" begin="8755" end="8800" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="963" sofa="1531" begin="8802" end="8973" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="970" sofa="1531" begin="8974" end="9117" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="977" sofa="1531" begin="9118" end="9274" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="984" sofa="1531" begin="9275" end="9450" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="991" sofa="1531" begin="9451" end="9611" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="998" sofa="1531" begin="9612" end="9775" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1005" sofa="1531" begin="9778" end="9871" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1012" sofa="1531" begin="9872" end="9958" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1019" sofa="1531" begin="9959" end="10003" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1026" sofa="1531" begin="10004" end="10050" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1033" sofa="1531" begin="10051" end="10095" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1040" sofa="1531" begin="10096" end="10142" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1047" sofa="1531" begin="10143" end="10189" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1054" sofa="1531" begin="10190" end="10233" wasGeneratedBy="79"/>
    <text:Sentence xmi:id="1061" sofa="1531" begin="10236" end="10266" wasGeneratedBy="79"/>
    <structure:Paragraph xmi:id="1068" sofa="1531" begin="4352" end="4376" wasGeneratedBy="107" rhetorical="par_1"/>
    <structure:Paragraph xmi:id="1075" sofa="1531" begin="4378" end="4613" wasGeneratedBy="107" rhetorical="par_2"/>
    <structure:Paragraph xmi:id="1082" sofa="1531" begin="4615" end="4643" wasGeneratedBy="107" rhetorical="par_3"/>
    <structure:Paragraph xmi:id="1089" sofa="1531" begin="4644" end="4757" wasGeneratedBy="107" rhetorical="par_4"/>
    <structure:Paragraph xmi:id="1096" sofa="1531" begin="4759" end="4782" wasGeneratedBy="107" rhetorical="par_5"/>
    <structure:Paragraph xmi:id="1103" sofa="1531" begin="4783" end="4803" wasGeneratedBy="107" rhetorical="par_6"/>
    <structure:Paragraph xmi:id="1110" sofa="1531" begin="4804" end="4827" wasGeneratedBy="107" rhetorical="par_7"/>
    <structure:Paragraph xmi:id="1117" sofa="1531" begin="4828" end="4918" wasGeneratedBy="107" rhetorical="par_8"/>
    <structure:Paragraph xmi:id="1124" sofa="1531" begin="4919" end="5007" wasGeneratedBy="107" rhetorical="par_9"/>
    <structure:Paragraph xmi:id="1131" sofa="1531" begin="5008" end="5915" wasGeneratedBy="107" rhetorical="par_10"/>
    <structure:Paragraph xmi:id="1138" sofa="1531" begin="5917" end="5939" wasGeneratedBy="107" rhetorical="par_11"/>
    <structure:Paragraph xmi:id="1145" sofa="1531" begin="5940" end="6096" wasGeneratedBy="107" rhetorical="par_12"/>
    <structure:Paragraph xmi:id="1152" sofa="1531" begin="6097" end="6185" wasGeneratedBy="107" rhetorical="par_13"/>
    <structure:Paragraph xmi:id="1159" sofa="1531" begin="6186" end="6511" wasGeneratedBy="107" rhetorical="par_14"/>
    <structure:Paragraph xmi:id="1166" sofa="1531" begin="6513" end="6535" wasGeneratedBy="107" rhetorical="par_15"/>
    <structure:Paragraph xmi:id="1173" sofa="1531" begin="6536" end="6688" wasGeneratedBy="107" rhetorical="par_16"/>
    <structure:Paragraph xmi:id="1180" sofa="1531" begin="6689" end="6777" wasGeneratedBy="107" rhetorical="par_17"/>
    <structure:Paragraph xmi:id="1187" sofa="1531" begin="6778" end="7623" wasGeneratedBy="107" rhetorical="par_18"/>
    <structure:Paragraph xmi:id="1194" sofa="1531" begin="7626" end="7655" wasGeneratedBy="107" rhetorical="par_19"/>
    <structure:Paragraph xmi:id="1201" sofa="1531" begin="7656" end="7672" wasGeneratedBy="107" rhetorical="par_20"/>
    <structure:Paragraph xmi:id="1208" sofa="1531" begin="7673" end="7701" wasGeneratedBy="107" rhetorical="par_21"/>
    <structure:Paragraph xmi:id="1215" sofa="1531" begin="7702" end="7755" wasGeneratedBy="107" rhetorical="par_22"/>
    <structure:Paragraph xmi:id="1222" sofa="1531" begin="7756" end="7807" wasGeneratedBy="107" rhetorical="par_23"/>
    <structure:Paragraph xmi:id="1229" sofa="1531" begin="7808" end="7871" wasGeneratedBy="107" rhetorical="par_24"/>
    <structure:Paragraph xmi:id="1236" sofa="1531" begin="7872" end="7932" wasGeneratedBy="107" rhetorical="par_25"/>
    <structure:Paragraph xmi:id="1243" sofa="1531" begin="7934" end="7953" wasGeneratedBy="107" rhetorical="par_26"/>
    <structure:Paragraph xmi:id="1250" sofa="1531" begin="7954" end="8092" wasGeneratedBy="107" rhetorical="par_27"/>
    <structure:Paragraph xmi:id="1257" sofa="1531" begin="8094" end="8119" wasGeneratedBy="107" rhetorical="par_28"/>
    <structure:Paragraph xmi:id="1264" sofa="1531" begin="8120" end="8243" wasGeneratedBy="107" rhetorical="par_29"/>
    <structure:Paragraph xmi:id="1271" sofa="1531" begin="8244" end="8432" wasGeneratedBy="107" rhetorical="par_30"/>
    <structure:Paragraph xmi:id="1278" sofa="1531" begin="8433" end="8616" wasGeneratedBy="107" rhetorical="par_31"/>
    <structure:Paragraph xmi:id="1285" sofa="1531" begin="8619" end="8639" wasGeneratedBy="107" rhetorical="par_32"/>
    <structure:Paragraph xmi:id="1292" sofa="1531" begin="8640" end="8754" wasGeneratedBy="107" rhetorical="par_33"/>
    <structure:Paragraph xmi:id="1299" sofa="1531" begin="8755" end="8800" wasGeneratedBy="107" rhetorical="par_34"/>
    <structure:Paragraph xmi:id="1306" sofa="1531" begin="8802" end="8823" wasGeneratedBy="107" rhetorical="par_35"/>
    <structure:Paragraph xmi:id="1313" sofa="1531" begin="8824" end="8973" wasGeneratedBy="107" rhetorical="par_36"/>
    <structure:Paragraph xmi:id="1320" sofa="1531" begin="8974" end="9117" wasGeneratedBy="107" rhetorical="par_37"/>
    <structure:Paragraph xmi:id="1327" sofa="1531" begin="9118" end="9274" wasGeneratedBy="107" rhetorical="par_38"/>
    <structure:Paragraph xmi:id="1334" sofa="1531" begin="9275" end="9450" wasGeneratedBy="107" rhetorical="par_39"/>
    <structure:Paragraph xmi:id="1341" sofa="1531" begin="9451" end="9611" wasGeneratedBy="107" rhetorical="par_40"/>
    <structure:Paragraph xmi:id="1348" sofa="1531" begin="9612" end="9775" wasGeneratedBy="107" rhetorical="par_41"/>
    <structure:Paragraph xmi:id="1355" sofa="1531" begin="9778" end="9802" wasGeneratedBy="107" rhetorical="par_42"/>
    <structure:Paragraph xmi:id="1362" sofa="1531" begin="9803" end="9825" wasGeneratedBy="107" rhetorical="par_43"/>
    <structure:Paragraph xmi:id="1369" sofa="1531" begin="9826" end="9871" wasGeneratedBy="107" rhetorical="par_44"/>
    <structure:Paragraph xmi:id="1376" sofa="1531" begin="9872" end="9958" wasGeneratedBy="107" rhetorical="par_45"/>
    <structure:Paragraph xmi:id="1383" sofa="1531" begin="9959" end="10003" wasGeneratedBy="107" rhetorical="par_46"/>
    <structure:Paragraph xmi:id="1390" sofa="1531" begin="10004" end="10050" wasGeneratedBy="107" rhetorical="par_47"/>
    <structure:Paragraph xmi:id="1397" sofa="1531" begin="10051" end="10095" wasGeneratedBy="107" rhetorical="par_48"/>
    <structure:Paragraph xmi:id="1404" sofa="1531" begin="10096" end="10142" wasGeneratedBy="107" rhetorical="par_49"/>
    <structure:Paragraph xmi:id="1411" sofa="1531" begin="10143" end="10189" wasGeneratedBy="107" rhetorical="par_50"/>
    <structure:Paragraph xmi:id="1418" sofa="1531" begin="10190" end="10233" wasGeneratedBy="107" rhetorical="par_51"/>
    <structure:Paragraph xmi:id="1425" sofa="1531" begin="10236" end="10249" wasGeneratedBy="107" rhetorical="par_52"/>
    <structure:Paragraph xmi:id="1432" sofa="1531" begin="10250" end="10265" wasGeneratedBy="107" rhetorical="par_53"/>
    <meta2:TableOfContents xmi:id="1439" sofa="1531" begin="10264" end="10265" wasGeneratedBy="107" outlines="386 395 521 404 413 530 539 422 431 440 449 548 458 467 476 485 494 557 566 503 512 575 584 593"/>
    <tcas:DocumentAnnotation xmi:id="1519" sofa="1538" begin="0" end="6257" language="x-unspecified"/>
    <cas:Sofa xmi:id="1524" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Overview:&#9;&#10;Brief Title:&#9;Minocycline in Patients With Alzheimer's Disease&#10;Official Title:&#9;MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy&#10;NCT-ID:&#9;NCT01463384&#10;Start Date:&#9;September 2011&#10;Completion Date:&#9;October 2012&#10;First Received Date:&#9;October 25, 2011&#10;Last Updated:&#9;September 23, 2014&#10;Verification Date:&#9;September 2014&#10;Authority:&#9;United States: Institutional Review Board&#10;Condition:&#9;Mild Cognitive Impairment;;Alzheimer's Disease&#10;Keyword:&#9;Magnetic Resonance Imaging;;Magnetic Resonance Spectroscopy;;Neuroinflammation;;Mild Cognitive Impairment;;Alzheimer's Disease;;Minocycline&#10;URL:&#9;http://clinicaltrials.gov/show/NCT01463384&#10;&#10;Brief Summary:&#9;Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.&#10;&#10;Detailed Description:&#9;In the course of on-going trials of novel MRI procedures for Neurological Diagnosis, the investigators have established non-invasive BIOMARKERS (Note: Biomarkers are objective Laboratory tests used in, but not replacing Clinical diagnostic criteria of any disease,in this case age-related dementia of the Alzheimer type and its pre-clinical forms including Mild Cognitive Impairment - MCI) which significantly assist in the Diagnosis of Alzheimer's Disease. MRS, rather like blood tests which are applied for screening and exclusion of medical disorders, provides a pattern of brain chemicals from which this and many other diagnoses have become available (see: Magnetic Resonance Spectroscopy in Neurological Diagnosis: E.R Danielsen and B.D. Ross, Marcel Dekker New York, 1999). Diagnosis of Alzheimer's Disease has hitherto been exclusively a clinical diagnosis, made on the basis of non-specific tests by the treating physician/neurologist. Furthermore, treatments have been of limited efficacy so that the pressure for conclusive diagnosis or an objective characterization of disease progression (or better, regression) has not been a priority. This conservative approach to Alzheimer's Disease changed in 2010 with the Report of National Institutes of Aging. First: The failures of treatment have been ascribed to introduction only in patients with advanced disease (&quot;dementia&quot;). Second: A preliminary form of AD, known as pre-clinical or Mild Cognitive Impairment, has been recognized, distinct from, and generally earlier in the disease course. Third: A new set of diagnostic criteria, which include objective 'biomarkers', from cerebrospinal fluid, genetic and imaging analyzes, has been accepted by the Expert Panel. Finally, Clinical trials of existing and new drugs for Alzheimer's Disease are expected to yield better results if initiated earlier - in the pre-clinical phase - and the outcomes evaluated by the earlier changes in an approved panel of biomarkers.&#10;&#10;Criteria:&#9;Inclusion Criteria.&#10; - Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease. Exclusion Criteria.&#10; - Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.&#10; - Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.&#10; - History of known allergy or intolerance to minocycline or any other tetracycline - Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.&#10;&#10;Further Study Details:&#9;&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 2&#10;Study Type:&#9;Interventional&#10;Healthy Volunteer:&#9;Accepts Healthy Volunteers&#10;Enrollment:&#9;13&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;90 Years&#10;&#10;Other ID's:&#9;Secondary ID: No information,Org Study ID: LKW-AB34&#10;PubMedID:&#9;No information&#10;&#10;1. Design Information:&#9;DesignName:EndpointClassification,DesignValue:EfficacyStudy.DesignName:InterventionModel,DesignValue:SingleGroupAssignment.DesignName:Masking,DesignValue:OpenLabel.DesignName:PrimaryPurpose,DesignValue:Treatment.&#10;&#10;2. Intervention Information:&#10;&#9;Intervention Type: Drug,Intervention Name: Minocycline,Intervention Description: 50mg, twice daily for 6 months.&#10;&#10;3. Outcome Information:&#10;3.1 Outcome Details:&#10;&#9;Outcome Type: Primary.&#10;Outcome Title: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial skills. RBANS was developed as a stand-alone ???????core???????? battery for the detection and neurocognitive characterization of dementia and as a brief neurocognitive battery for the detection and tracking of neurocognitive deficits in a variety of disorders. (Reference: http://rbans.com/) Qualitative Description of Index Scores: Index Score Classification 130 and above Very Superior 120-129 Superior 110-119 High Average 90-109 Average 80-89 Low Average 70-79 Borderline 69 and below Extremely Low Psychometric range for RBANS: AD 0 - 77 MCI 78 - 99 Normal &gt; 100 Range of scores: Minimum = 0, Maximum = 130 Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)..&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: Using magnetic resonance images acquired, hippocampal volume was measured monthly for 6 months. Normal range for hippocampal volume in aged-matched controls is 6.6 - 8.8 cm^3. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: It has been demonstrated in numerous studies over the past decade that magnetic resonance spectroscopy (MRS) can be used for the diagnosis of Alzheimer????????s disease. By measuring an area within the posterior cingulate gyrus, one can obtain a biochemical signature of that region in AD whereby NAA is reduced and mI is increased. These two biomarkers, N-acetylaspartate (NAA, a neuronal marker) and myo-inositol (mI, a glial marker) were quantified and then used to calculate NAA/mI (an index currently widely used for AD and MCI diagnosis). Scale of MRS biomarkers for aged-matched controls: NAA = 1.43, mI = 0.60, NAA/mI = 2.38. Any value lower than NAA/mI of 2.38 are considered not normal. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration.&#10;&#10;&#10;3.2 Outcome Analysis Details:&#10;&#9;No information.&#10;3.3 Outcome Measure Details:&#10;&#9;Outcome Units of Measure: Ratio,Measure Type: Mean .&#10;Outcome Units of Measure: cm^3,Measure Type: Mean .&#10;Outcome Units of Measure: units on a scale,Measure Type: Mean .&#10;Outcome Units of Measure: participants,Measure Type: Number.&#10;&#10;3.4 Outcome Values:&#10;&#9;1,8,4,32.5,32.9,81,58.7,63.8,106,108.4,123.6,49,5.49,5.42,4.94,6.35,6.30,7.60,6.98,6.92,6.82,2.44,2.47,1.69,1.78,1.84,1.87,1.80,2.08,2.42&#10;&#10;4. Study Outcome Details:&#10;&#9;Study Outcome Type:  primary outcome,Measure: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) .&#10;Study Outcome Type:  primary outcome,Measure: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC). .&#10;Study Outcome Type:  primary outcome,Measure: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;&#10;&#10;5. Location Details:&#10;5.1 Facility Details:&#9;City: Pasadena,Country: United States,Facility Name: Huntington Medical Research Institutes.&#10;5.2 Facility Contact Details:&#9;No information.&#10;&#10;6. Arm Group Details:&#10;&#9;Arm Group Label:  Minocycline,Arm Group Type: Active Comparator,Arm Group DEscription: Subjects will be administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline,Arm Group Type: Baseline,Arm Group DEscription: Subjects administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline,Arm Group Type: Participant Flow,Arm Group DEscription: Subjects were administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline MCI,Arm Group Type: Results Outcome,Arm Group DEscription: Mild cognitively impaired subject who was administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline AD,Arm Group Type: Results Outcome,Arm Group DEscription: Alzheimer subjects who were administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline NC,Arm Group Type: Results Outcome,Arm Group DEscription: Normal control subjects who were administered 50mg minocycline twice daily.&#10;&#10;&#10;7. Baseline Information:&#10;7.1 Baseline ID:&#9;13745&#10;7.2 Baseline Measure Details:&#9;No information.&#10;7.3 Baseline Measure Cateogary Details:&#9;Cateogary Title:  Female,Baseline Value: 308 .&#10;Cateogary Title:  Male,Baseline Value: 433 .&#10;Cateogary Title:  Female,Baseline Value: 178 .&#10;Cateogary Title:  Male,Baseline Value: 191 .&#10;Cateogary Title:  Female,Baseline Value: 190 .&#10;Cateogary Title:  Female,Baseline Value: 676 .&#10;Cateogary Title:  Male,Baseline Value: 815.&#10;&#10;&#10;8. Reference:&#10;&#9;No information&#10;"/>
    <cas:Sofa xmi:id="1531" sofaNum="2" sofaID="DocumentView" mimeType="text" sofaString="Overview:&#9;&#10;Brief Title:&#9;Minocycline in Patients With Alzheimer's Disease&#10;Official Title:&#9;MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy&#10;NCT-ID:&#9;NCT01463384&#10;Start Date:&#9;September 2011&#10;Completion Date:&#9;October 2012&#10;First Received Date:&#9;October 25, 2011&#10;Last Updated:&#9;September 23, 2014&#10;Verification Date:&#9;September 2014&#10;Authority:&#9;United States: Institutional Review Board&#10;Condition:&#9;Mild Cognitive Impairment;;Alzheimer's Disease&#10;Keyword:&#9;Magnetic Resonance Imaging;;Magnetic Resonance Spectroscopy;;Neuroinflammation;;Mild Cognitive Impairment;;Alzheimer's Disease;;Minocycline&#10;URL:&#9;http://clinicaltrials.gov/show/NCT01463384&#10;&#10;Brief Summary:&#9;Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.&#10;&#10;Detailed Description:&#9;In the course of on-going trials of novel MRI procedures for Neurological Diagnosis, the investigators have established non-invasive BIOMARKERS (Note: Biomarkers are objective Laboratory tests used in, but not replacing Clinical diagnostic criteria of any disease,in this case age-related dementia of the Alzheimer type and its pre-clinical forms including Mild Cognitive Impairment - MCI) which significantly assist in the Diagnosis of Alzheimer's Disease. MRS, rather like blood tests which are applied for screening and exclusion of medical disorders, provides a pattern of brain chemicals from which this and many other diagnoses have become available (see: Magnetic Resonance Spectroscopy in Neurological Diagnosis: E.R Danielsen and B.D. Ross, Marcel Dekker New York, 1999). Diagnosis of Alzheimer's Disease has hitherto been exclusively a clinical diagnosis, made on the basis of non-specific tests by the treating physician/neurologist. Furthermore, treatments have been of limited efficacy so that the pressure for conclusive diagnosis or an objective characterization of disease progression (or better, regression) has not been a priority. This conservative approach to Alzheimer's Disease changed in 2010 with the Report of National Institutes of Aging. First: The failures of treatment have been ascribed to introduction only in patients with advanced disease (&quot;dementia&quot;). Second: A preliminary form of AD, known as pre-clinical or Mild Cognitive Impairment, has been recognized, distinct from, and generally earlier in the disease course. Third: A new set of diagnostic criteria, which include objective 'biomarkers', from cerebrospinal fluid, genetic and imaging analyzes, has been accepted by the Expert Panel. Finally, Clinical trials of existing and new drugs for Alzheimer's Disease are expected to yield better results if initiated earlier - in the pre-clinical phase - and the outcomes evaluated by the earlier changes in an approved panel of biomarkers.&#10;&#10;Criteria:&#9;Inclusion Criteria.&#10; - Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease. Exclusion Criteria.&#10; - Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.&#10; - Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.&#10; - History of known allergy or intolerance to minocycline or any other tetracycline - Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.&#10;&#10;Further Study Details:&#9;&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 2&#10;Study Type:&#9;Interventional&#10;Healthy Volunteer:&#9;Accepts Healthy Volunteers&#10;Enrollment:&#9;13&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;90 Years&#10;&#10;Other ID's:&#9;Secondary ID: No information,Org Study ID: LKW-AB34&#10;PubMedID:&#9;No information&#10;&#10;1. Design Information:&#9;DesignName:EndpointClassification,DesignValue:EfficacyStudy.DesignName:InterventionModel,DesignValue:SingleGroupAssignment.DesignName:Masking,DesignValue:OpenLabel.DesignName:PrimaryPurpose,DesignValue:Treatment.&#10;&#10;2. Intervention Information:&#10;&#9;Intervention Type: Drug,Intervention Name: Minocycline,Intervention Description: 50mg, twice daily for 6 months.&#10;&#10;3. Outcome Information:&#10;3.1 Outcome Details:&#10;&#9;Outcome Type: Primary.&#10;Outcome Title: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: RBANS is a brief neurocognitive battery with four alternate forms, measuring immediate and delayed memory, attention, language, and visuospatial skills. RBANS was developed as a stand-alone ???????core???????? battery for the detection and neurocognitive characterization of dementia and as a brief neurocognitive battery for the detection and tracking of neurocognitive deficits in a variety of disorders. (Reference: http://rbans.com/) Qualitative Description of Index Scores: Index Score Classification 130 and above Very Superior 120-129 Superior 110-119 High Average 90-109 Average 80-89 Low Average 70-79 Borderline 69 and below Extremely Low Psychometric range for RBANS: AD 0 - 77 MCI 78 - 99 Normal &gt; 100 Range of scores: Minimum = 0, Maximum = 130 Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)..&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: Using magnetic resonance images acquired, hippocampal volume was measured monthly for 6 months. Normal range for hippocampal volume in aged-matched controls is 6.6 - 8.8 cm^3. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration. &#10;&#10;Outcome Type: Primary.&#10;Outcome Title: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;Time Frame: Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged).&#10;Outcome Description: It has been demonstrated in numerous studies over the past decade that magnetic resonance spectroscopy (MRS) can be used for the diagnosis of Alzheimer????????s disease. By measuring an area within the posterior cingulate gyrus, one can obtain a biochemical signature of that region in AD whereby NAA is reduced and mI is increased. These two biomarkers, N-acetylaspartate (NAA, a neuronal marker) and myo-inositol (mI, a glial marker) were quantified and then used to calculate NAA/mI (an index currently widely used for AD and MCI diagnosis). Scale of MRS biomarkers for aged-matched controls: NAA = 1.43, mI = 0.60, NAA/mI = 2.38. Any value lower than NAA/mI of 2.38 are considered not normal. Values are reported below for Baseline, averaged for 1-3 months, and averaged for 4-6 months during minocycline administration.&#10;&#10;&#10;3.2 Outcome Analysis Details:&#10;&#9;No information.&#10;3.3 Outcome Measure Details:&#10;&#9;Outcome Units of Measure: Ratio,Measure Type: Mean .&#10;Outcome Units of Measure: cm^3,Measure Type: Mean .&#10;Outcome Units of Measure: units on a scale,Measure Type: Mean .&#10;Outcome Units of Measure: participants,Measure Type: Number.&#10;&#10;3.4 Outcome Values:&#10;&#9;1,8,4,32.5,32.9,81,58.7,63.8,106,108.4,123.6,49,5.49,5.42,4.94,6.35,6.30,7.60,6.98,6.92,6.82,2.44,2.47,1.69,1.78,1.84,1.87,1.80,2.08,2.42&#10;&#10;4. Study Outcome Details:&#10;&#9;Study Outcome Type:  primary outcome,Measure: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) .&#10;Study Outcome Type:  primary outcome,Measure: Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC). .&#10;Study Outcome Type:  primary outcome,Measure: Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).&#10;&#10;&#10;5. Location Details:&#10;5.1 Facility Details:&#9;City: Pasadena,Country: United States,Facility Name: Huntington Medical Research Institutes.&#10;5.2 Facility Contact Details:&#9;No information.&#10;&#10;6. Arm Group Details:&#10;&#9;Arm Group Label:  Minocycline,Arm Group Type: Active Comparator,Arm Group DEscription: Subjects will be administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline,Arm Group Type: Baseline,Arm Group DEscription: Subjects administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline,Arm Group Type: Participant Flow,Arm Group DEscription: Subjects were administered 50mg minocycline twice daily for 6 months .&#10;Arm Group Label:  Minocycline MCI,Arm Group Type: Results Outcome,Arm Group DEscription: Mild cognitively impaired subject who was administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline AD,Arm Group Type: Results Outcome,Arm Group DEscription: Alzheimer subjects who were administered 50mg minocycline twice daily. .&#10;Arm Group Label:  Minocycline NC,Arm Group Type: Results Outcome,Arm Group DEscription: Normal control subjects who were administered 50mg minocycline twice daily.&#10;&#10;&#10;7. Baseline Information:&#10;7.1 Baseline ID:&#9;13745&#10;7.2 Baseline Measure Details:&#9;No information.&#10;7.3 Baseline Measure Cateogary Details:&#9;Cateogary Title:  Female,Baseline Value: 308 .&#10;Cateogary Title:  Male,Baseline Value: 433 .&#10;Cateogary Title:  Female,Baseline Value: 178 .&#10;Cateogary Title:  Male,Baseline Value: 191 .&#10;Cateogary Title:  Female,Baseline Value: 190 .&#10;Cateogary Title:  Female,Baseline Value: 676 .&#10;Cateogary Title:  Male,Baseline Value: 815.&#10;&#10;&#10;8. Reference:&#10;&#9;No information&#10;"/>
    <cas:Sofa xmi:id="1538" sofaNum="3" sofaID="ContentView" mimeType="text" sofaString="Table of Contents:&#10;    Overview: Overview:&#9; ____________________________________________________ 0 &#10;    Brief Summary: Brief Summary:&#9; ________________________________________ 669 &#10;      DETAILS  ___________________________________________________________ 1263 &#10;    Detailed Description: Detailed Descri ________________________________ 1264 &#10;    Criteria: Criteria:&#9;Inclu ____________________________________________ 3263 &#10;      Inclusion Criteria. Inclusion Crite ________________________________ 3273 &#10;      Exclusion Criteria. Exclusion Crite ________________________________ 3474 &#10;    Further Study Details: Further Study D _______________________________ 4077 &#10;    Design Information: Design Informat __________________________________ 4381 &#10;    Intervention Information: Intervention In ____________________________ 4618 &#10;    Outcome Information: Outcome Informa _________________________________ 4762 &#10;      Outcome Details: Outcome Details ___________________________________ 4787 &#10;    Outcome Analysis Details: ration. ____________________________________ 7616 &#10;    Outcome Measure Details: ormation. ___________________________________ 7663 &#10;    Outcome Values:  Number. _____________________________________________ 7924 &#10;    Study Outcome Details: 2.08,2.42 _____________________________________ 8083 &#10;    Location Details: ls (NC). ___________________________________________ 8608 &#10;      Facility Details:  Details: ________________________________________ 8630 &#10;      Facility Contact Details: stitutes. ________________________________ 8745 &#10;    Arm Group Details: ormation. _________________________________________ 8791 &#10;    Baseline Information: e daily. _______________________________________ 9767 &#10;      Baseline ID: ormation: _____________________________________________ 9793 &#10;      Baseline Measure Details: ID:&#9;13745 ________________________________ 9816 &#10;      Baseline Measure Cateogary Details: ormation. ______________________ 9862 &#10;&#10;    par_1: PubMedID:&#9;No in _______________________________________________ 4352 &#10;    par_2: 1. Design Infor _______________________________________________ 4378 &#10;    par_3: 2. Intervention _______________________________________________ 4615 &#10;    par_4: &#9;Intervention T _______________________________________________ 4644 &#10;    par_5: 3. Outcome Info _______________________________________________ 4759 &#10;    par_6: 3.1 Outcome Det _______________________________________________ 4783 &#10;    par_7: &#9;Outcome Type:  _______________________________________________ 4804 &#10;    par_8: Outcome Title:  _______________________________________________ 4828 &#10;    par_9: Time Frame: Bas _______________________________________________ 4919 &#10;    par_10: Outcome Descrip ______________________________________________ 5008 &#10;    par_11: Outcome Type: P ______________________________________________ 5917 &#10;    par_12: Outcome Title:  ______________________________________________ 5940 &#10;    par_13: Time Frame: Bas ______________________________________________ 6097 &#10;    par_14: Outcome Descrip ______________________________________________ 6186 &#10;    par_15: Outcome Type: P ______________________________________________ 6513 &#10;    par_16: Outcome Title:  ______________________________________________ 6536 &#10;    par_17: Time Frame: Bas ______________________________________________ 6689 &#10;    par_18: Outcome Descrip ______________________________________________ 6778 &#10;    par_19: 3.2 Outcome Ana ______________________________________________ 7626 &#10;    par_20: &#9;No information ______________________________________________ 7656 &#10;    par_21: 3.3 Outcome Mea ______________________________________________ 7673 &#10;    par_22: &#9;Outcome Units  ______________________________________________ 7702 &#10;    par_23: Outcome Units o ______________________________________________ 7756 &#10;    par_24: Outcome Units o ______________________________________________ 7808 &#10;    par_25: Outcome Units o ______________________________________________ 7872 &#10;    par_26: 3.4 Outcome Val ______________________________________________ 7934 &#10;    par_27: &#9;1,8,4,32.5,32. ______________________________________________ 7954 &#10;    par_28: 4. Study Outcom ______________________________________________ 8094 &#10;    par_29: &#9;Study Outcome  ______________________________________________ 8120 &#10;    par_30: Study Outcome T ______________________________________________ 8244 &#10;    par_31: Study Outcome T ______________________________________________ 8433 &#10;    par_32: 5. Location Det ______________________________________________ 8619 &#10;    par_33: 5.1 Facility De ______________________________________________ 8640 &#10;    par_34: 5.2 Facility Co ______________________________________________ 8755 &#10;    par_35: 6. Arm Group De ______________________________________________ 8802 &#10;    par_36: &#9;Arm Group Labe ______________________________________________ 8824 &#10;    par_37: Arm Group Label ______________________________________________ 8974 &#10;    par_38: Arm Group Label ______________________________________________ 9118 &#10;    par_39: Arm Group Label ______________________________________________ 9275 &#10;    par_40: Arm Group Label ______________________________________________ 9451 &#10;    par_41: Arm Group Label ______________________________________________ 9612 &#10;    par_42: 7. Baseline Inf ______________________________________________ 9778 &#10;    par_43: 7.1 Baseline ID ______________________________________________ 9803 &#10;    par_44: 7.2 Baseline Me ______________________________________________ 9826 &#10;    par_45: 7.3 Baseline Me ______________________________________________ 9872 &#10;    par_46: Cateogary Title ______________________________________________ 9959 &#10;    par_47: Cateogary Title _____________________________________________ 10004 &#10;    par_48: Cateogary Title _____________________________________________ 10051 &#10;    par_49: Cateogary Title _____________________________________________ 10096 &#10;    par_50: Cateogary Title _____________________________________________ 10143 &#10;    par_51: Cateogary Title _____________________________________________ 10190 &#10;    par_52: 8. Reference: _______________________________________________ 10236 &#10;    par_53: &#9;No information _____________________________________________ 10250 &#10;"/>
    <meta:DateTime xmi:id="1545" day="28" month="5" year="2016" hour="16" minute="36" second="50"/>
    <meta:DateTime xmi:id="1552" day="28" month="5" year="2016" hour="16" minute="38" second="24"/>
    <meta:Parameter xmi:id="1559" key="event" value="ExtractHeader ExtractFrontMatter" wasGeneratedBy="22"/>
    <meta:DateTime xmi:id="1563" day="28" month="5" year="2016" hour="16" minute="36" second="50"/>
    <meta:DateTime xmi:id="1570" day="28" month="5" year="2016" hour="16" minute="38" second="24"/>
    <meta:DateTime xmi:id="1577" day="28" month="5" year="2016" hour="13" minute="53" second="59"/>
    <meta:DateTime xmi:id="1584" day="28" month="5" year="2016" hour="13" minute="53" second="59"/>
    <meta:Parameter xmi:id="1591" key="license" value="" wasGeneratedBy="56"/>
    <meta:Parameter xmi:id="1595" key="recipients" value="" wasGeneratedBy="56"/>
    <meta:DateTime xmi:id="1599" day="28" month="5" year="2016" hour="16" minute="38" second="24"/>
    <meta:DateTime xmi:id="1606" day="28" month="5" year="2016" hour="16" minute="38" second="24"/>
    <meta:DateTime xmi:id="1613" day="28" month="5" year="2016" hour="16" minute="38" second="24"/>
    <meta:DateTime xmi:id="1620" day="28" month="5" year="2016" hour="16" minute="38" second="24"/>
    <meta:DateTime xmi:id="1627" day="28" month="5" year="2016" hour="16" minute="38" second="24"/>
    <meta:DateTime xmi:id="1634" day="28" month="5" year="2016" hour="16" minute="38" second="25"/>
    <meta:DateTime xmi:id="1641" day="28" month="5" year="2016" hour="16" minute="38" second="25"/>
    <meta:DateTime xmi:id="1648" day="28" month="5" year="2016" hour="16" minute="38" second="25"/>
    <meta:Person xmi:id="1655" surname="" forename=""/>
    <meta:Date xmi:id="1660" day="25" month="10" year="2011"/>
    <meta:Concept xmi:id="1664" prefLabel="1670" identifier="NCT01463384" identifierSource="clinicaltrials.gov"/>
    <meta:Label xmi:id="1670" value="ctgov:NCT01463384"/>
    <cas:View sofa="1524" members="1 6 11 16 18 20 22 39 56 79 92 107 117 132 136 140 144 148 152 156 160 164 168 172 176 180 184 188 192 196 200 204 208 212 216 220 224 228 232 236 240 244 248 252 256 260 264 268 272 276 280 284 288 292 296 300 304 308 312 316 320 324 328 333 349"/>
    <cas:View sofa="1531" members="367 372 380 386 395 404 413 422 431 440 449 458 467 476 485 494 503 512 521 530 539 548 557 566 575 584 593 602 613 620 627 634 641 648 655 662 669 676 683 690 697 704 711 718 725 732 739 746 753 760 767 774 781 788 795 802 809 816 823 830 837 844 851 858 865 872 879 886 893 900 907 914 921 928 935 942 949 956 963 970 977 984 991 998 1005 1012 1019 1026 1033 1040 1047 1054 1061 1068 1075 1082 1089 1096 1103 1110 1117 1124 1131 1138 1145 1152 1159 1166 1173 1180 1187 1194 1201 1208 1215 1222 1229 1236 1243 1250 1257 1264 1271 1278 1285 1292 1299 1306 1313 1320 1327 1334 1341 1348 1355 1362 1369 1376 1383 1390 1397 1404 1411 1418 1425 1432 1439"/>
    <cas:View sofa="1538" members="1519"/>
</xmi:XMI>
